CNET Highlights Top FDA-Cleared Red Light Therapy Devices as Market Nears $660 Million by 2032

Why It Matters

The CNET ranking underscores how regulatory approval is becoming a decisive factor for consumers navigating an increasingly saturated red‑light therapy market. FDA clearance not only assures safety but also signals that a device has met a minimum efficacy threshold, which can accelerate adoption among health‑conscious buyers and drive premium pricing. As the sector scales toward a $658 million valuation, manufacturers that secure clearance early may capture market share and attract investment, while those that rely solely on marketing hype risk being sidelined. Moreover, the spotlight on diverse use cases—from facial rejuvenation to hair regrowth—highlights the expanding therapeutic scope of red‑light technology. This diversification could spur further clinical research, potentially unlocking new FDA indications and reinforcing the credibility of at‑home phototherapy. For insurers and healthcare providers, validated devices may eventually become reimbursable options, integrating consumer wellness tools into broader treatment plans.

Key Takeaways

• CNET’s 2026 roundup names four FDA‑cleared red light devices as the market’s top picks.
• Market size grew from $421 M in 2024 to $444 M in 2025; projected $658 M by 2032.
• Shark CryoGlow ($350) is the only FDA‑cleared mask that also offers cryotherapy.
• iRestore Elite ($1,799) is the sole at‑home device cleared with triple‑wavelength tech and a 12‑month hair‑growth guarantee.
• Regulatory clearance is becoming a key differentiator as premium pricing and consumer trust rise.

Pulse Analysis

The red‑light therapy segment is transitioning from a niche wellness fad to a mainstream health‑tech category, driven largely by FDA clearance acting as a trust anchor. Historically, the market was fragmented, with many low‑cost LED products making unverified claims. The recent surge in clearance‑backed offerings suggests manufacturers are investing in clinical trials and regulatory pathways, a move that could reshape the competitive landscape. Companies that secure clearance early gain a dual advantage: they can command higher price points and access distribution channels that require compliance, such as pharmacy chains and medical‑device retailers.

From an investment perspective, the projected $658 million market size by 2032 signals a robust growth runway. Venture capital and strategic corporate investors are likely to prioritize firms that demonstrate a clear regulatory strategy, as this reduces product‑launch risk and aligns with the increasing scrutiny of consumer health devices by both regulators and insurers. The convergence of phototherapy with AI and biometric data could further differentiate next‑generation devices, creating barriers to entry for low‑cost competitors and opening new revenue streams through subscription‑based treatment plans.

For consumers, the emphasis on FDA clearance simplifies decision‑making in a crowded marketplace. However, the premium pricing of cleared devices raises questions about accessibility and equity. As the industry matures, we may see tiered product lines—cleared entry‑level models paired with higher‑end, data‑rich devices—allowing broader adoption while preserving the credibility that clearance provides. The next few years will likely see a push toward standardizing treatment protocols, which could eventually lead to insurance reimbursement and integration into clinical practice, further legitimizing at‑home red‑light therapy as a therapeutic modality.